Read about a novel antibody moving into human trials for autoimmune gastrointestinal and neurological diseases and its potential to broaden therapeutic options.
Key Takeaways
- NMPA granted approval to start clinical trials of 9MW5211 for inflammatory bowel disease
- FDA previously cleared 9MW5211 for clinical testing in the United States
- Preclinical studies showed efficacy in mouse autoimmune models and favorable monkey safety